Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,170 across all filing types
Latest filing 2025-03-18 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the incorporation of a wholly owned subsidiary of Lupin Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document is short (2043 characters) and serves as an intimation or announcement rather than a detailed report or financial statement. There is no financial data, management discussion, or detailed report content. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into more specific categories like Annual Report, Interim Report, or Capital Update.
2025-03-18 English
The Company has incorporated a wholly owned subsidiary in the name and style ''LUPINLIFE Consumer Healthcare Limited'' under Corporate Identification Number U21002MH2025PLC443065.
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement informing about the incorporation of a wholly owned subsidiary by Lupin Limited. It references compliance with SEBI Listing Regulations and previous disclosure letters but does not contain any financial data, detailed reports, or presentations. The length is only 2043 characters, indicating it is a brief notice rather than a full report. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into other specific categories like Annual Report, Interim Report, or Capital Update.
2025-03-18 English
Lupin Receives Tentative Approval from U.S. FDA for Amifampridine Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for an Abbreviated New Drug Application. It is addressed to stock exchanges and regulatory bodies under SEBI Listing Obligations, indicating a regulatory disclosure. The document is short (3760 characters), contains no financial statements or detailed financial data, and primarily serves as an announcement of a regulatory event rather than a financial report or detailed filing. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is the announcement itself, not about a report release. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-03-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Amifampridine Tablets. It is addressed to stock exchanges and references regulatory disclosure requirements (SEBI Listing Regulations). The content is a corporate announcement about a regulatory milestone and product approval, not a financial report, earnings release, or detailed investor presentation. The document length is 3760 characters, which is relatively short and typical for a press release. There is no financial data, no management discussion, no voting results, no audit information, or other report content. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2025-03-17 English
Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Rivaroxaban Tablets USP, 2.5 mg) following FDA approval. It is addressed to stock exchanges and regulatory bodies under SEBI Listing Obligations and Disclosure Requirements. The content is promotional and informative about a product launch, not a financial report, earnings release, or regulatory filing about financials or corporate governance. It does not contain financial statements, management discussion, or voting results. It is a typical corporate announcement or press release about a business development event. Such documents do not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the options, the closest relevant category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-07 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the launch of a pharmaceutical product (Rivaroxaban Tablets USP, 2.5 mg) following FDA approval. It is addressed to stock exchanges and includes regulatory references (SEBI Listing Obligations). The content is promotional and informative about a product launch, not a financial report, earnings release, or regulatory filing about financials. It does not contain financial statements, management discussion, or voting results. It is a corporate announcement related to product launch and regulatory approval, which fits best under Capital/Financing Update (CAP) as it relates to a significant business development impacting company operations and potentially capital markets. The document length is short (3816 characters), and it is not an announcement of a report publication or certification. Therefore, the best classification is Capital/Financing Update (CAP).
2025-03-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.